Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients

J Dermatol. 2022 Apr;49(4):e125-e126. doi: 10.1111/1346-8138.16286. Epub 2021 Dec 27.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Humans
  • Insulin Resistance*
  • Phosphodiesterase 4 Inhibitors* / pharmacology
  • Phosphodiesterase 4 Inhibitors* / therapeutic use
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Thalidomide / analogs & derivatives
  • Thalidomide / pharmacology
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Phosphodiesterase 4 Inhibitors
  • Thalidomide
  • apremilast